Diversion and Abuse of Buprenorphine

More documents

Recommendations

Info

5000 4500 4000 3500 3000 2500 2000 1500 1000 Exhibit 40. Items Analyzed by Forensic Laboratories and Reported through NFLIS: 2005 (incomplete as of 3/21/06) 500 0 A A A A C C C D D F K L R Z Q O T C E L G H A I Buprenorphine Assessment: Final Report HYDROCODONE METHADONE OXYCODONE BUPRENORPHINE I A I D I L I N K K L M M M M M M M M N N N N N N O O O P P S S T S Y A A D E I N O S T C E J M V Y H K R A R C D N Source: U.S. Drug Enforcement Administration, National Forensic Laboratory Information System T U X T V W W W W A A I V Y 60
400 350 300 250 200 150 100 50 0 A K A L A R A Z Exhibit 41. Buprenorphine Items Analyzed by Forensic Laboratories and Reported through NFLIS: 2002-2005 C C C A O T D C D E F G H L A I Buprenorphine Assessment: Final Report I A I D I L I N 2002 2003 2004 2005 K K L M M M M M M M M N S Y A A D E I N O S T C N N N N E J M V N O O O P P Y H K R A R S C S D T T U N X T V W W W W A A I V Y Source: U.S. Drug Enforcement Administration, National Forensic Laboratory Information System 61
Page 1:
Diversion and Abuse of Buprenorphin
Page 5 and 6:
Diversion and Abuse of Buprenorphin
Page 7 and 8:
The actual review of the literature
Page 9 and 10:
Risk Factors: The use of buprenorph
Page 11 and 12:
prescribed dose to other persons wh
Page 13 and 14: In a separate report of data gather
Page 15 and 16: leading to heavy reliance on office
Page 17 and 18: 1. While adverse drug events associ
Page 19 and 20: At Columbia University, Herbert Kle
Page 21 and 22: Bridge TP, Fudala PJ, Herbert S et
Page 23 and 24: Gaul & Flaherty (2003b). Internet t
Page 25 and 26: Office of Applied Studies (2006a).
Page 27 and 28: APPENDIX A FEDERAL AND STATE OFFICI
Page 29 and 30: APPENDIX B INFORMATION SOURCES CONS
Page 31 and 32: APPENDIX C OUTSIDE EXPERTS CONSULTE
Page 33 and 34: TECHNICAL REPORT: ANALYSIS OF AVAIL
Page 35 and 36: Exhibit 3. Based on this estimate (
Page 37 and 38: Exhibit 5. DAWNLive! Continuously R
Page 39 and 40: 100% 90% 80% 70% 60% 50% 40% 30% 20
Page 41 and 42: Exhibit 12. DAWNLive! All Reporting
Page 43 and 44: increasing, especially cases involv
Page 45 and 46: See exhibits 37-44 for a full listi
Page 47 and 48: the TEDS other opiate patients were
Page 49 and 50: In the last two years, patients who
Page 51 and 52: self-medicating with buprenorphine.
Page 53 and 54: legally available in the U.S.) has
Page 55 and 56: engaging in activities such as rent
Page 57 and 58: Exhibit 33. Characteristics of Verm
Page 59 and 60: Exhibit 35. DAWN Live! ED Reports b
Page 61 and 62: 3000 2500 2000 1500 1000 500 0 Exhi
Page 63: 8000 7000 6000 5000 4000 3000 2000
Page 67 and 68: Exhibit 43. Oxycodone Items Analyze
Page 69 and 70: Exhibit 45. Total Number of Subutex
show all

Diversion and Abuse of Buprenorphine

Create successful ePaper yourself

Delete template?

Save as template?